Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

Quick Answer

Therapeutic PD-L1 antibodies showed stronger functional blockade of PD-1/PD-L1 signaling than tested PD-1 antibodies in a 2019 Scientific Reports T-cell reporter assay. In that study, atezolizumab, avelumab, and durvalumab had lower EC50 values than nivolumab and pembrolizumab, suggesting stronger in vitro blocking potency. However, this does not mean PD-L1 antibodies are clinically better in every cancer. Cancer immunotherapy outcomes depend on tumor type, PD-L1 expression, immune microenvironment, biomarker status, antibody design, dose, and clinical trial evidence.

Introduction

Cancer immunotherapy has changed how researchers and clinicians approach tumor treatment. Instead of only targeting cancer cells directly, immunotherapy helps the immune system recognize and attack tumors more effectively. One of the most important breakthroughs in this field is the use of immune checkpoint inhibitors that target the PD-1/PD-L1 pathway. PD-1 antibodies and PD-L1 antibodies are both designed to block immune-suppressive signaling. PD-1 antibodies such as pembrolizumab and nivolumab bind the PD-1 receptor on T cells. PD-L1 antibodies such as atezolizumab, avelumab, and durvalumab bind the PD-L1 ligand, which is often expressed on tumor cells and antigen-presenting cells.

The key question is simple but important: are therapeutic PD-L1 antibodies more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling? A functional study suggests that, in vitro, PD-L1 antibodies can block this pathway more efficiently. But the full answer requires a mechanism, original study data, clinical context, and research application.

What Is the PD-1/PD-L1 Pathway?

PD-1, also known as programmed cell death protein 1, is an inhibitory receptor expressed on activated T cells. PD-L1, also known as programmed death-ligand 1, is expressed on tumor cells, immune cells, and other cells within the tumor microenvironment. When PD-L1 binds to PD-1, it sends an inhibitory signal into the T cell. This reduces T-cell activation and weakens the anti-tumor immune response. Many tumors use this pathway to avoid immune attack.

Blocking PD-1 PD-L1 signaling in cancer immunotherapy can restore T-cell activity and help immune cells respond against cancer cells. This is why immune checkpoint inhibitors targeting PD-1 or PD-L1 are widely studied in oncology.

Original Study Data: PD-L1 Antibodies Showed Lower EC50 Values

The strongest evidence for this topic comes from a 2019 Scientific Reports study titled “Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.”

The researchers used a T-cell reporter platform to compare five clinically used antibodies:

• Nivolumab
• Pembrolizumab
• Atezolizumab
• Avelumab
• Durvalumab

The study measured functional EC50 values. EC50 means the antibody concentration needed to achieve half-maximal functional blocking activity. A lower EC50 value means stronger blocking activity in that specific assay.

These results show that pembrolizumab was slightly more effective than nivolumab in PD-1 inhibition. More importantly, all three tested PD-L1 antibodies had much lower EC50 values than the two PD-1 antibodies. This supports the statement that therapeutic PD-L1 antibodies were more effective than PD-1 antibodies in reverting PD-1 signaling in that functional assay.

How the Functional Assay Worked

The study did not rely only on theoretical comparison. It used a controlled T-cell reporter system. The researchers used PD-1-expressing Jurkat T-cell reporter cells and stimulator cells expressing PD-L1. When PD-L1 interacted with PD-1, T-cell reporter activation was reduced. When PD-1 or PD-L1 antibodies were added, the antibodies blocked this inhibitory interaction and restored reporter activity.

The antibodies were tested across a concentration range, and reporter gene expression was measured after 24 hours using flow cytometry. This allowed the researchers to calculate functional EC50 values for each antibody. This is important because it makes the comparison stronger than a simple binding test: the assay measured functional pathway blockade, not just antibody attachment to the target.

Functional Blocking Assay vs Binding Assay

One of the most important findings was that binding strength did not fully predict functional blocking activity. In the binding assay, PD-1 antibodies and PD-L1 antibodies showed target binding to their respective antigens. However, the binding assay did not explain why pembrolizumab blocked PD-1 signaling better than nivolumab, or why PD-L1 antibodies had stronger functional blockade than PD-1 antibodies.

This means that standard binding assays may not be enough to evaluate immune checkpoint inhibitors. For antibody development and cancer immunotherapy research, functional assays are essential because they show whether an antibody actually blocks signaling activity.

Why PD-L1 Antibodies May Block PD-1/PD-L1 Signaling More Effectively

The study suggested that one possible reason is that ligands may be more effectively blocked than receptors in this experimental system. PD-L1 is the major PD-1 ligand in many tumor microenvironments, and direct ligand-side blockade may strongly interrupt the inhibitory signal. PD-L1 antibodies may also affect PD-L1/CD80 biology. PD-L1 can bind CD80/B7-1, a molecule involved in T-cell costimulation. By targeting PD-L1, PD-L1 antibodies may disrupt both PD-L1/PD-1 and PD-L1/CD80 interactions.

Another important difference is PD-L2. PD-1 antibodies block PD-1 interaction with both PD-L1 and PD-L2. PD-L1 antibodies block PD-L1 but generally preserve PD-1/PD-L2 interaction. This may influence immune activity and safety profiles in different biological settings.

PD-1 Antibodies vs PD-L1 Antibodies

Efficacy of Pembrolizumab Versus Nivolumab in PD-1 Inhibition

Pembrolizumab and nivolumab are among the most recognized PD-1 antibodies in cancer immunotherapy. Both block PD-1 and are used in multiple cancer types. In the 2019 functional assay, pembrolizumab showed stronger PD-1 inhibition than nivolumab. Pembrolizumab had an EC50 value of 39.90 ng/ml, while nivolumab had an EC50 value of 76.17 ng/ml.

This means pembrolizumab required a lower concentration than nivolumab to reverse PD-1-mediated inhibition in that assay. However, this does not automatically mean pembrolizumab is clinically superior in every cancer indication. Clinical efficacy depends on approved indication, dosing schedule, tumor biology, PD-L1 expression, tumor mutational burden, prior therapy, and patient-specific factors.

Comparison of PD-1 and PD-L1 Inhibitors in Cancer Therapy

The comparison of PD-1 and PD-L1 inhibitors in cancer therapy must be handled carefully. From a mechanism perspective, PD-1 inhibitors offer broader receptor-side blockade because they prevent PD-1 from interacting with both PD-L1 and PD-L2. This may be useful in immune priming, where dendritic cells and antigen-presenting cells can express both PD-L1 and PD-L2. PD-L1 inhibitors provide ligand-side blockade. They block PD-L1, which is often highly expressed in the tumor microenvironment, while generally allowing PD-1/PD-L2 interaction to continue. This may create a more selective immune-modulating effect.

From a clinical perspective, no single statement fits every cancer. Some reviews and analyses show similar efficacy between PD-1 and PD-L1 inhibitors in certain settings, while other data suggest possible differences in immune-related adverse events such as pneumonitis. Therefore, the best scientific conclusion is balanced: PD-L1 antibodies may show stronger functional blockade in vitro, but clinical superiority depends on cancer type, patient selection, biomarkers, treatment setting, and clinical trial evidence.

Why This Topic Matters for Cancer Immunotherapy Research

This topic is important because immune checkpoint inhibitors are not only clinical drugs; they are also central tools in immunology, oncology, and antibody development research.

Researchers studying PD-1/PD-L1 signaling often need to evaluate:

• Antibody blocking potency
• PD-1 and PD-L1 binding interaction
• T-cell activation
• Tumor immune escape
• Functional EC50 values
• Immune checkpoint inhibitor screening
• PD-L1 expression models
• Receptor-ligand blockade
• Antibody comparison assays

For these workflows, recombinant PD-1 and PD-L1 proteins are important research reagents. They support binding assays, antibody screening, ELISA-based studies, flow cytometry validation, and immune checkpoint pathway research.

Beta LifeScience provides recombinant immune checkpoint proteins and related research tools that can support PD-1/PD-L1 binding studies, antibody screening, and cancer immunotherapy research applications.

Research Tools Used in PD-1/PD-L1 Studies

A strong PD-1/PD-L1 research workflow may include:

• Recombinant human PD-1 protein
• Recombinant human PD-L1 protein
• Biotinylated PD-1 protein
• Biotinylated PD-L1 protein
• PD-1/PD-L1 binding assay reagents
• Immune checkpoint protein panels
• Antibody screening tools
• Reporter cell assays
• Flow cytometry-based binding assays
• ELISA-based ligand-receptor assays

This is where product integration becomes natural. Instead of only mentioning a brand at the end, the article should connect Beta LifeScience products to real research use cases, such as checkpoint protein binding, antibody screening, and pathway-blocking assay development.

 PD-1/PD-L1 Pathway Diagram

Add a clean pathway diagram showing:

1. A tumor cell expressing PD-L1
2. A T cell expressing PD-1
3. PD-L1 binding to PD-1
4. T-cell activity is being suppressed
5. Anti-PD-1 or anti-PD-L1 antibody blocks the interaction
6. Restored T-cell activation and tumor-cell killing

This visual will help readers understand the mechanism quickly.

EC50 Comparison Chart

Add a bar chart showing functional EC50 values:

• Nivolumab: 76.17 ng/ml
• Pembrolizumab: 39.90 ng/ml
• Atezolizumab: 6.46 ng/ml
• Avelumab: 6.15 ng/ml
• Durvalumab: 7.64 ng/ml

Add a note under the chart:

“Lower EC50 indicates stronger functional blockade in this assay.”

This chart can make your article stronger than normal competitor blogs because it converts research paper data into an easy visual format.

PD-1 vs PD-L1 Antibody Mechanism Infographic

Create a two-column infographic:

Left side: PD-1 antibodies

• Pembrolizumab
• Nivolumab
• Bind PD-1 receptor
• Block PD-L1 and PD-L2 interaction

Right side: PD-L1 antibodies

• Atezolizumab
• Avelumab
• Durvalumab
• Bind PD-L1 ligand
• Preserve PD-L2 signaling
• May affect PD-L1/CD80 interaction

This infographic can support SEO, AEO, and GEO because it answers comparison-based search intent clearly.

Antibody Binding Illustration

Add a simple scientific illustration showing:

• PD-1 antibody binding PD-1 on T cells
• PD-L1 antibody binding PD-L1 on the tumor cell
• Receptor-side blockade vs ligand-side blockade

This image will make the article more engaging and easier to understand.

FAQs

Are PD-L1 antibodies more effective than PD-1 antibodies?

In a 2019 functional T-cell reporter assay, PD-L1 antibodies showed lower EC50 values than PD-1 antibodies, suggesting stronger blockade of PD-1/PD-L1 signaling in vitro.

Which PD-L1 antibodies were tested in the study?

The study tested atezolizumab, avelumab, and durvalumab as PD-L1 antibodies.

Which PD-1 antibodies were tested in the study?

The study tested nivolumab and pembrolizumab as PD-1 antibodies.

Is pembrolizumab more effective than nivolumab?

In the functional assay, pembrolizumab showed a lower EC50 value than nivolumab, suggesting slightly stronger PD-1 inhibition in that experimental system.

Does lower EC50 mean better cancer treatment?

Not always. Lower EC50 means stronger potency in a specific assay, but clinical outcomes depend on many factors, including tumor type, biomarkers, dosing, safety, and patient selection.

Why do PD-L1 antibodies preserve PD-L2 signaling?

PD-L1 antibodies target PD-L1, not PD-1. Because PD-1 itself remains unblocked, PD-1 can still interact with PD-L2 unless another therapy blocks that interaction.

Why are functional assays important in immune checkpoint inhibitor research?

Functional assays show whether an antibody actually blocks immune checkpoint signaling. Binding assays only show target attachment and may not fully predict functional pathway blockade.

Conclusion:

Therapeutic PD-L1 antibodies were more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling in a functional T-cell reporter assay. Atezolizumab, avelumab, and durvalumab showed lower EC50 values than nivolumab and pembrolizumab, meaning they achieved stronger pathway blockade at lower concentrations in that model. Pembrolizumab was also slightly more effective than nivolumab in PD-1 inhibition.

Still, in-vitro functional potency should not be confused with universal clinical superiority. Cancer immunotherapy depends on tumor type, biomarkers, immune context, approved indications, safety profile, and clinical trial results. For researchers, the main value of this topic is clear: functional assays, recombinant PD-1/PD-L1 proteins, and reliable immune checkpoint reagents are essential for understanding how PD-1 antibodies and PD-L1 antibodies differ in cancer immunotherapy research.

References

1. De Sousa Linhares A, Battin C, Jutz S, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Scientific Reports. 2019;9:11472. DOI: 10.1038/s41598-019-47910-1. PMID: 31391510.
2. Zou W, Wolchok JD, Chen L. PD-L1/B7-H1 and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Science Translational Medicine. 2016.
3. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. Journal for ImmunoTherapy of Cancer. 2018.
4. Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018.
5. Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017.
6. Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017.
7. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007.
8. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology. 2015.